

Select Clinical Trials of Cabozantinib

As of our Q4/FY 2016 financial results call, February 27, 2017; for a full list of ongoing studies, please visit www.clinicaltrials.gov

| Indication | Combination Regimen | Status Update |
|---|----------------------------|--|
| Progressive, Metastatic Medullary Thyroid Cancer (MTC) | | |
| | | Approved in US and EU; Post-marketing study EXAMINER ongoing |
| Renal Cell Carcinoma (RCC) | | |
| Second-line | | Approved in US and EU |
| First-line (intermediate- or poor-risk classification) | | Preparing to file sNDA in 2017 based on results from CABOSUN† trial |
| First-line | + nivolumab +/- ipilimumab | Phase 3 pivotal trial expected to begin in 2017, co-funded with Bristol-Myers Squibb |
| Hepatocellular Carcinoma | | |
| Second-line | | Phase 3 (CELESTIAL), data anticipated in 2017 |
| Non-Small Cell Lung Cancer | | |
| EGFR wild-type | | Phase 2† |
| Molecular alterations in RET, ROS1, MET, AXL, or NTRK1 | | Phase 2* |
| Genitourinary Tumors, including Bladder and Urothelial Cancers | | |
| Genitourinary tumors | + nivolumab +/- ipilimumab | Phase 1† |
| Advanced solid tumors | + atezolizumab | Phase 1B trial to begin in 2017, planned cohorts in RCC and urothelial carcinoma |
| Signal Search Opportunities to Inform Potential Development | | |
| Pancreatic neuroendocrine and carcinoid tumors | | Phase 2* |
| Endometrial cancer | | Phase 2† |
| Differentiated thyroid cancer | | Phase 2* |
| Metastatic gastrointestinal stromal tumor | | Phase 2 (CABOGIST)§ |
| Breast cancer with brain metastases | +/- trastuzumab | Phase 2* |
| Metastatic, hormone-receptor-positive breast cancer | + fulvestrant | Phase 2* |
| Metastatic, triple negative breast cancer | | Phase 2* |
| Soft-tissue sarcomas | | Phase 2† |
| High-grade uterine sarcomas | | Phase 2§ |
| Relapsed osteosarcoma or Ewing sarcoma | | Phase 2† |
| Colorectal cancer | +/- panitumumab | Phase 1* |

* Trial conducted through Exelixis' Investigator-Sponsored Trial program.

† Trial conducted through collaboration with NCI's Cancer Therapy Evaluation Program.

§ Trial sponsored by the European Organisation for Research and Treatment of Cancer (EORTC).